Details for Patent: 7,815,934
✉ Email this page to a colleague
Which drugs does patent 7,815,934 protect, and when does it expire?
Patent 7,815,934 protects EMBEDA and TROXYCA ER and is included in two NDAs.
This patent has sixteen patent family members in twelve countries.
Summary for Patent: 7,815,934
Title: | Sequestering subunit and related compositions and methods |
Abstract: | A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent. |
Inventor(s): | Boehm; Garth (Westfield, NJ) |
Assignee: | Alpharma Pharmaceuticals, LLC (Bridgewater, NJ) |
Application Number: | 10/667,676 |
Patent Claim Types: see list of patent claims | Use; Composition; | More… ↓ |
Drugs Protected by US Patent 7,815,934
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-001 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-002 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-003 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-004 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-005 | Aug 13, 2009 | DISCN | Yes | No | 7,815,934 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,815,934
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2003270778 | ⤷ Subscribe | |||
Australia | 2009251081 | ⤷ Subscribe | |||
Canada | 2499550 | ⤷ Subscribe | |||
China | 1703200 | ⤷ Subscribe | |||
Cyprus | 1120720 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |